贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300558 贝达药业

交易中 05-13 09:39:09

{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":49.82,"timestamp":1747100349000,"preClose":49.44,"halted":0,"volume":1003200,"delay":0,"changeRate":0.0077,"floatShares":417000000,"shares":418000000,"eps":0.9667,"marketStatus":"交易中","change":0.38,"latestTime":"05-13 09:39:09","open":49.97,"high":50.05,"low":49.56,"amount":49945100,"amplitude":0.0099,"askPrice":49.83,"askSize":6,"bidPrice":49.79,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.9667,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1747107000000},"marketStatusCode":2,"adr":0,"adjPreClose":49.44,"symbolType":"stock","openAndCloseTimeList":[[1747099800000,1747107000000],[1747112400000,1747119600000]],"highLimit":54.38,"lowLimit":44.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":418485885,"isCdr":false,"pbRate":3.73,"roa":"--","peRate":51.536154,"roe":"1.8%","epsLYR":0.96,"committee":-0.178947,"marketValue":20849000000,"turnoverRate":0.0024,"status":0,"floatMarketCap":20781000000},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2534717746","title":"贝达药业(300558)4月30日股东户数2.65万户，较上期增加4.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534717746","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534717746?lang=zh_cn&edition=full","pubTime":"2025-05-09 17:54","pubTimestamp":1746784482,"startTime":"0","endTime":"0","summary":"证券之星消息，近日贝达药业披露，截至2025年4月30日公司股东户数为2.65万户，较3月31日增加1189.0户，增幅为4.7%。在化学制药行业个股中，贝达药业股东户数低于行业平均水平，截至4月30日，化学制药行业平均股东户数为3.21万户。从股价来看，2025年3月31日至2025年4月30日，贝达药业区间跌幅为1.31%，在此期间股东户数增加1189.0户，增幅为4.7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900028665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2534260561","title":"贝达药业：在香港证券交易所申请发行股份属于重大筹资活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2534260561","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534260561?lang=zh_cn&edition=full","pubTime":"2025-05-09 15:08","pubTimestamp":1746774502,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，恒瑞医药已经开始发行港股筹资，加大创新药研发，贝达药业今年也有重启发行港股筹资加大创新药研发吗？贝达药业回复：您好！在香港证券交易所申请发行股份属于重大筹资活动，如有计划公司会按照法规规则要求及时履行审议、披露程序。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900017494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2531739544","title":"贝达药业：公司目前经营现金流良好可以满足包括研发临床投入等的日常经营需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2531739544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531739544?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:54","pubTimestamp":1745931270,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司目前账上资金能否满足公司研发正常需要，后期研发水平是不是要大打折扣；其次是公司上市以来是否回购过股份；贝达药业回复：您好！公司目前经营现金流良好，可以满足包括研发、临床投入等的日常经营需求。公司自2016年上市以来未实施股份回购，如有回购股份等重大事项，会及时公开披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900040265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","159399","BK0060"],"gpt_icon":0},{"id":"2531220030","title":"贝达药业：贝福替尼一线治疗中位PFS长达22.1个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2531220030","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531220030?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:48","pubTimestamp":1745912902,"startTime":"0","endTime":"0","summary":"根据贝福替尼Ⅲ期临床研究显示，其一线治疗中位PFS长达22.1个月，是目前三代EGFR抑制剂一线治疗更好的PFS表现，同时其胃肠道副作用在目前三代EGFR抑制剂中相对较小。目前，贝福替尼一线、二线适应症均已纳入国家医保，公司借助其纳入医保的契机为其制定并落实了针对性的推广策略，积极推进药品在全国医院、药店的准入，提升其在医院、药房的覆盖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900025422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2531748220","title":"贝达药业：公司计划在DURAVYU美国获批上市后开展桥接研究支持在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2531748220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531748220?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:48","pubTimestamp":1745912899,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业04月29日在投资者关系平台上答复投资者关心的问题。经综合评估临床投入、开发效率以及其他不确定性因素影响，公司计划在DURAVYU美国获批上市后，开展桥接研究来支持在中国的获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900025417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2531722071","title":"贝达药业：贝福替尼未开展20外显子插入突变和EGFR少见突变的相关注册研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2531722071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531722071?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:48","pubTimestamp":1745912897,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公开资料显示，阿美替尼、伏美替尼等三代药都在开展治疗EGFR 20ins突变和EGFR少见突变的晚期NSCLC患者的疗效与安全临床，且数据优秀，疗效显著。作为同类三代药，贝福替尼是否有开展类似临床研究扩大适应症？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900025411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2531207022","title":"贝达药业：MCLA-129是一款针对EGFR和c-Met双靶点的双特异性抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=2531207022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531207022?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:45","pubTimestamp":1745912721,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司接下来在大分子双抗三抗有哪些布局贝达药业回复：您好！在研管线中，MCLA-129是一款针对EGFR和c-Met双靶点的双特异性抗体，拟用于EGFR或MET异常的晚期实体瘤患者的治疗，目前其临床试验正在推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900025004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2529934507","title":"贝达药业(300558.SZ)发布一季度业绩，归母净利润1亿元，增长1.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529934507","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529934507?lang=zh_cn&edition=full","pubTime":"2025-04-24 22:14","pubTimestamp":1745504090,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布2025年第一季度报告，该公司营业收入为9.18亿元，同比增长24.71%。归属于上市公司股东的净利润为1亿元，同比增长1.99%。归属于上市公司股东的扣除非经常性损益的净利润为1.64亿元，同比增长83.59%。基本每股收益为0.24元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300558"],"gpt_icon":0},{"id":"2514787826","title":"贝达药业(300558)1月27日股东户数2.45万户，较上期减少9.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514787826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514787826?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:11","pubTimestamp":1740647519,"startTime":"0","endTime":"0","summary":"证券之星消息，近日贝达药业披露，截至2025年1月27日公司股东户数为2.45万户，较12月31日减少2548.0户，减幅为9.44%。在化学制药行业个股中，贝达药业股东户数低于行业平均水平，截至1月27日，化学制药行业平均股东户数为3.09万户。从股价来看，2024年12月31日至2025年1月27日，贝达药业区间涨幅为5.1%，在此期间股东户数减少2548.0户，减幅为9.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700029545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2513176417","title":"贝达药业(300558.SZ)聘任LI MAO担任研发总裁兼首席医学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2513176417","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513176417?lang=zh_cn&edition=full","pubTime":"2025-02-24 16:49","pubTimestamp":1740386956,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)公告，由于公司经营管理的需要，经董事长提名、第四届董事会提名委员会第二次会议任职资格审核通过，董事会同意聘任LI MAO担任公司研发总裁兼首席医学官，分管公司新药研发和医学临床研究等部门的工作，任期自董事会审议通过之日起至本届董事会届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4526","BK4548","BK0060","BK4563","300558","BK4503","BK4099","BK4551","BK4555","BK4585","BK0239","EVS.SI"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747100352231,"stockEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0279},{"period":"3month","weight":-0.0638},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.1593},{"period":"ytd","weight":-0.0833}],"compareEarnings":[{"period":"1week","weight":0.0275},{"period":"1month","weight":0.0405},{"period":"3month","weight":0.0154},{"period":"6month","weight":-0.0204},{"period":"1year","weight":0.0681},{"period":"ytd","weight":0.0052}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26504人(较上一季度增加4.70%)","perCapita":"15738股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"41848万元","survey":"　　贝达药业股份有限公司的主营业务是创新药物的生产与销售。公司的主要产品是凯美纳、贝美纳、赛美纳、伏美纳。公司获得过“浙江省文明单位”称号、全省高质量发展领军企业、深交所上市公司信息披露工作考核第五次获评A级、第十三届中国公益节“责任品牌奖”和“公益创新奖”，荣获浙江省科学技术进步一等奖、浙江省药学会科学技术特等奖。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}